BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

232 related articles for article (PubMed ID: 32409202)

  • 1. Testosterone replacement therapy (TRT) and prostate cancer: An updated systematic review with a focus on previous or active localized prostate cancer.
    Lenfant L; Leon P; Cancel-Tassin G; Audouin M; Staerman F; Rouprêt M; Cussenot O
    Urol Oncol; 2020 Aug; 38(8):661-670. PubMed ID: 32409202
    [TBL] [Abstract][Full Text] [Related]  

  • 2. [Testosterone replacement therapy for hypogonadism in men with prostate cancer].
    Jensen CF; Fode M; Østergren P; Sønksen J
    Ugeskr Laeger; 2017 Feb; 179(9):. PubMed ID: 28263152
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Recurrence of prostate cancer in patients receiving testosterone supplementation for hypogonadism.
    Gray H; Seltzer J; Talbert RL
    Am J Health Syst Pharm; 2015 Apr; 72(7):536-41. PubMed ID: 25788507
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Prostate-specific antigen changes and prostate cancer in hypogonadal men treated with testosterone replacement therapy.
    Coward RM; Simhan J; Carson CC
    BJU Int; 2009 May; 103(9):1179-83. PubMed ID: 19154450
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Testosterone replacement therapy in hypogonadal men at high risk for prostate cancer: results of 1 year of treatment in men with prostatic intraepithelial neoplasia.
    Rhoden EL; Morgentaler A
    J Urol; 2003 Dec; 170(6 Pt 1):2348-51. PubMed ID: 14634413
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Oncological safety of testosterone replacement therapy in prostate cancer survivors after definitive local therapy: A systematic literature review and meta-analysis.
    Kardoust Parizi M; Abufaraj M; Fajkovic H; Kimura S; Iwata T; D'Andrea D; Karakiewicz PI; Shariat SF
    Urol Oncol; 2019 Oct; 37(10):637-646. PubMed ID: 31296421
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Testosterone treatment is not associated with increased risk of prostate cancer or worsening of lower urinary tract symptoms: prostate health outcomes in the Registry of Hypogonadism in Men.
    Debruyne FM; Behre HM; Roehrborn CG; Maggi M; Wu FC; Schröder FH; Jones TH; Porst H; Hackett G; Wheaton OA; Martin-Morales A; Meuleman E; Cunningham GR; Divan HA; Rosen RC;
    BJU Int; 2017 Feb; 119(2):216-224. PubMed ID: 27409523
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Testosterone replacement therapy in the setting of prostate cancer treated with radiation.
    Pastuszak AW; Pearlman AM; Godoy G; Miles BJ; Lipshultz LI; Khera M
    Int J Impot Res; 2013 Jan; 25(1):24-8. PubMed ID: 22971614
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Is testosterone treatment good for the prostate? Study of safety during long-term treatment.
    Feneley MR; Carruthers M
    J Sex Med; 2012 Aug; 9(8):2138-49. PubMed ID: 22672563
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Androgen replacement in men undergoing treatment for prostate cancer.
    Rhoden EL; Averbeck MA; Teloken PE
    J Sex Med; 2008 Sep; 5(9):2202-8. PubMed ID: 18638000
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Testosterone replacement therapy in patients with prostate cancer after radical prostatectomy.
    Pastuszak AW; Pearlman AM; Lai WS; Godoy G; Sathyamoorthy K; Liu JS; Miles BJ; Lipshultz LI; Khera M
    J Urol; 2013 Aug; 190(2):639-44. PubMed ID: 23395803
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Testosterone replacement for hypogonadism after treatment of early prostate cancer with brachytherapy.
    Sarosdy MF
    Cancer; 2007 Feb; 109(3):536-41. PubMed ID: 17183557
    [TBL] [Abstract][Full Text] [Related]  

  • 13. The effect of testosterone replacement therapy on prostate cancer: a systematic review and meta-analysis.
    Cui Y; Zong H; Yan H; Zhang Y
    Prostate Cancer Prostatic Dis; 2014 Jun; 17(2):132-43. PubMed ID: 24445948
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Testosterone Replacement Therapy and the Risk of Prostate Cancer in Men With Late-Onset Hypogonadism.
    Santella C; Renoux C; Yin H; Yu OHY; Azoulay L
    Am J Epidemiol; 2019 Sep; 188(9):1666-1673. PubMed ID: 31145457
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Influence of demographic factors and biochemical characteristics on the prostate-specific antigen (PSA) response to testosterone replacement therapy.
    Rhoden EL; Morgentaler A
    Int J Impot Res; 2006; 18(2):201-5. PubMed ID: 16177827
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Prostate magnetic resonance imaging findings in patients treated for testosterone deficiency while on active surveillance for low-risk prostate cancer.
    Hashimoto T; Rahul K; Takeda T; Benfante N; Mulhall JP; Hricak H; Eastham JA; Vargas HA
    Urol Oncol; 2016 Dec; 34(12):530.e9-530.e14. PubMed ID: 27665357
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Testosterone Replacement Therapy in Hypogonadal Men Following Prostate Cancer Treatment: A Questionnaire-Based Retrospective Study among Urologists in Bavaria, Germany.
    Kühn CM; Strasser H; Romming A; Wullich B; Goebell PJ
    Urol Int; 2015; 95(2):153-9. PubMed ID: 25677365
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Effects of Testosterone Replacement Therapy on Lower Urinary Tract Symptoms: A Systematic Review and Meta-analysis.
    Kohn TP; Mata DA; Ramasamy R; Lipshultz LI
    Eur Urol; 2016 Jun; 69(6):1083-90. PubMed ID: 26874809
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Safety of androgen therapy in men with prostate cancer.
    Rajan P; Tharakan T; Chen R
    Best Pract Res Clin Endocrinol Metab; 2022 Sep; 36(5):101628. PubMed ID: 35248487
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Androgen replacement after curative radical prostatectomy for prostate cancer in hypogonadal men.
    Kaufman JM; Graydon RJ
    J Urol; 2004 Sep; 172(3):920-2. PubMed ID: 15310998
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 12.